Fundraising Fox
Antidote Therapeutics
Gaithersburg, US · Founded 2013 · Delaware corporation
Find your way into Antidote Therapeutics
Sign up to see every warm intro you have to Antidote Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antidote Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Antidote Therapeutics is a biotechnology company focused on drug discovery and development, led by an experienced team with backgrounds in clinical trials, pharmaceutical development, and biomarker-driven innovation.
Founders & leadership
MK
Matthew KalnikFounder and Chief Executive OfficerHe brings extensive experience in biopharmaceutical business development, drug discovery, and M&A, having led or contributed to over 35 licensing and merger transactions across therapeutic areas ranging from small molecules and biologics to diagnostics, and has authored publications and patents in his field.
KC
Kenneth C. CarterNamed on SEC filing
MW
Matthew W. Kalnik, PhDNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$632.3K disclosed across 2 rounds · 2017
▶$200KraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth C. CarterDirector
- Matthew W. Kalnik, PhDExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$432.3KraisedSep 2017 · 2 investors · BiotechnologyRule 506(b)
▶$432.3KraisedSep 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth C. CarterDirector
- Matthew W. Kalnik, PhDExecutive Officer, Director
- Offering amount
- $432.3K
- Amount sold
- $432.3K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Antidote Therapeutics.
Frequently asked questions
- What does Antidote Therapeutics do?
- Antidote Therapeutics is a biotechnology company focused on drug discovery and development, led by an experienced team with backgrounds in clinical trials, pharmaceutical development, and biomarker-driven innovation.
- How much funding has Antidote Therapeutics raised?
- Antidote Therapeutics has disclosed $632.3K raised across 2 rounds.
- Where is Antidote Therapeutics headquartered?
- Antidote Therapeutics is headquartered in Gaithersburg, US.